Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Radiopharmaceuticals in the Treatment of Metastatic Castration-Resistant Prostate Cancer

In this podcast episode, listen to Chris Parker, MD, and Bertrand Tombal, MD, PhD, as they discuss clinical implications of the latest data from ASCO 2021 on using radium-223, PSMA lutetium, and bone health approaches for the treatment and management of patients with metastatic castration-resistant prostate cancer.
Chris Parker, MD
Bertrand Tombal, MD, PhD
Released: July 20, 2021

Acknowledgements

Supported by an educational grant from
Bayer HealthCare

Information on this Educational Activity

Faculty

Chris Parker, MD

Professor of Prostate Oncology
Institute of Cancer Research
Clinical Oncologist
Department of Uro-oncology
Royal Marsden Hospital
Sutton, Surrey, United Kingdom

Chris Parker, MD, has disclosed that he has received consulting fees from Bayer and Myovant and fees for non-CME/CE services from Janssen.
Bertrand Tombal, MD, PhD

Professor of Urology
Institut de Recherche Clinique (IREC)
Chairman, Department of Surgery
Cliniques universitaires Saint-Luc
Brussels, Belgium

Bertrand Tombal, MD, PhD, has disclosed that he has received funds for research support from Astellas and Bayer; consulting fees from Amgen, Astellas, Bayer, Ferring, Janssen, Novartis/Advanced Accelerator Applications, Sanofi, and Myovant; and fees for non-CME/CE services from Amgen, Astellas, Bayer, Ferring, Janssen, Novartis/Advanced Accelerator Applications, Sanofi, and Myovant.

Program Medium

This program has been made available online.

Related Content

Slides from Clinical Care Options (CCO) on 2021 treatment recommendations for patients with nmCRPC.

David F. Penson, MD Released: September 10, 2021

Slides from Clinical Care Options (CCO) on best practices in classifying prostate cancer and using ADT

Daniel W. Lin, MD Released: September 10, 2021

Slides from Clinical Care Options (CCO) on 2021 treatment recommendations for patients with mHSPC.

Alicia K. Morgans, MD, MPH Released: September 10, 2021

Daniel P. Petrylak, MD, and Elizabeth R. Plimack, MD, MS, review key data in genitourinary cancers from the 2021 ASCO Annual Meeting, as reported by Clinical Care Options (CCO)

Daniel P. Petrylak, MD Elizabeth R. Plimack, MD, MS Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: September 7, 2021 Expired: September 6, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue